Latest from MD Anderson

Shubham Pant, MD, discusses choosing therapy for the frontline and beyond in pancreatic cancer.

The anti-DLL4/VEGF bispecific antibody navicixizumab showed promising clinical activity when used in combination with paclitaxel in heavily pretreated patients with platinum-resistant ovarian cancer.

Matthew T. Campbell, MD, discusses the evolving treatment options in the renal cell carcinoma paradigm.

OncLive interviewed experts at the State of the Science Summits^™ in March 2020 on the impact of the COVID-19 pandemic on cancer care and shared what advice they have been giving their patients.

Ahmed O. Kaseb, MD, a professor in the Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses research with targeted therapy in hepatocellular carcinoma (HCC).

Kanwal Raghav, MBBS, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses ongoing research with immunotherapy and targeted therapy in colorectal cancer (CRC).

Experts from Mayo Clinic, Ironwood Cancer and Research Centers, and Banner MD Anderson Cancer Center Clinic discuss the impact of the COVID-19 pandemic on cancer care and shared what advice they have been giving their patients.

Michael J. Overman, MD, discusses factors to consider when choosing between regorafenib and TAS-102 in the third-line treatment of patients with colorectal cancer.